Neurogene Therapeutics (NGNE) Cash Funds per Single Share

Neurogene Inc. is developing precision gene therapies, securing patents for Rett syndrome treatments. Its own US-based manufacturing facility ensures the production of complex biologics, although high R&D expenditures are depleting reserves. The cash per share trend demonstrates the current margin of safety, while the 17.41 metric reflects the current market value of this liquid asset.
Comprehensive metric breakdowns and analytics for neurogene.com (NGNE)

Investors must assess the bankruptcy risk of Neurogene Inc. (NGNE), given the lack of stable revenues in the clinical gene therapy sector. An analysis of cash per share allows for the determination of the actual liquidity reserve per unit, which serves as a critical indicator of business viability prior to drug commercialization and confirms its operational resilience against macroeconomic shocks.